Company News: Page (1) of 1 - 05/14/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Immunicum AB (publ) Announces Upcoming Presentations and Attendances at Conferences in May and June

(May 14, 2018)

Press Release

14 May 2018

Immunicum AB (publ) Announces Upcoming Presentations and Attendances at Conferences in May and June

Immunicum AB (publ; IMMU.ST) today announced that Company leadership will present the corporate overview, participate on an immuno-oncology panel and attend upcoming industry conferences in May and June.



Bio€quity Europe
Date: May 14 - 16, 2018
Presentation: Wednesday, May 16, 10:20 - 10:40 am Central European Summer Time
Venue: Universiteit Gent - Het Pand, Ghent, Belgium

RedEye Investor After Work Stockholm
Date: May 22, 2018
Presentation: 6:00 - 6:20 pm Central European Summer Time
Venue: Mäster Samuelsgatan 42, 111 57 Stockholm, Sweden
Please register to attend at: http://bit.ly/2HUwBGm   

Sachs Associates 4th Annual Immuno-Oncology: BD&L and Investment Forum
Date: June 1, 2018
Panel: Latest Developments in IO & Combination Therapies - 10:40 am Central Daylight Time
Presentation: 12:20 - 12:40 pm Central Daylight Time
Venue: Waldorf Astoria Chicago Hotel, Chicago, Illinois, USA

BIO International Convention
Date: June 4 - 7, 2018
Venue: Boston Convention & Exhibition Center, Boston, Massachusetts, USA

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: [email protected]  

Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75
E-mail: [email protected] 

Media Relations

Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: [email protected] 

About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm www.immunicum.com

 

Attachment


Page: 1


Related Keywords:

-->

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved